News Read the latest news from Astellas Gene Therapies Apr 22, 2022 Notice Regarding Impairment Loss for Products under Development Read More Feb 07, 2022 Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease Read More Dec 02, 2021 Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle Read More Sep 14, 2021 Astellas Reports Update to Sept. 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy Read More Sep 01, 2021 Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy Read More Mar 31, 2021 Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies Read More Dec 24, 2020 Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM) Read More Aug 20, 2020 Audentes Therapeutics Provides Update on the ASPIRO Clinical Trial Evaluating AT132 in Patients with X-linked Myotubular Myopathy Read More Feb 18, 2020 Audentes Therapeutics Announces Plans to Build New State-of-the-Art Gene Therapy Manufacturing Facility in Sanford, North Carolina Read More Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Next page Next › Last page Last »